Yifan Zhai Healthcare News

This is selected healthcare news for Yifan Zhai, which is filed under People. There are 19 news items for this page. A press release filter page is also available for Yifan Zhai.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
4/28/2022 ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting, Business News - AsiaOne
... 2022. "This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting," said Dr. Yifan Zhai , Chief Medical Officer. "We are pleased to be offered a further opportunity to showcase our company's progress on multiple clinical trials and demonstrate ...
asiaone.com
4/28/2022 ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting | News | bakersfield.com
... 2022. "This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting," said Dr. Yifan Zhai, Chief Medical Officer. "We are pleased to be offered a further opportunity to showcase our company's progress on multiple clinical trials and demonstrate ...
bakersfield.com
4/27/2022 ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
... 2022. "This is the fifth consecutive year in which Ascentage-sponsored clinical results have been selected for presentations at the ASCO Annual Meeting," said Dr. Yifan Zhai , Chief Medical Officer. "We are pleased to be offered a further opportunity to showcase our company's progress on multiple clinical trials and demonstrate ...
PR Newswire
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 | News | bakersfield.com
... cutting-edge advances in all the areas of cancer research and innovation, the annual event attracts tremendous interest from the global cancer research community. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said: "At this year's AACR Annual Meeting, we presented preclinical data that support potential combination approaches between ...
bakersfield.com
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
... cutting-edge advances in all the areas of cancer research and innovation, the annual event attracts tremendous interest from the global cancer research community. Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma, said: "At this year's AACR Annual Meeting, we presented preclinical data that support potential combination approaches between ...
Yahoo News
4/14/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
... cutting-edge advances in all the areas of cancer research and innovation, the annual event attracts tremendous interest from the global cancer research community. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said: "At this year's AACR Annual Meeting, we presented preclinical data that support potential combination approaches between ...
onenewspage.com
4/13/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
... cutting-edge advances in all the areas of cancer research and innovation, the annual event attracts tremendous interest from the global cancer research community. Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma, said: "At this year's AACR Annual Meeting, we presented preclinical data that support potential combination approaches between ...
PR Newswire
4/13/2022 AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 | Business & Finance | citizentribune.com
... cutting-edge advances in all the areas of cancer research and innovation, the annual event attracts tremendous interest from the global cancer research community. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said: "At this year's AACR Annual Meeting, we presented preclinical data that support potential combination approaches between ...
citizentribune.com
3/11/2021 Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
... this year, our presentations will focus on results from the translational research of multiple drug candidates that have already entered into clinical development," said Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma. "These studies deepened our understanding of our drug candidate's mechanism of actions, provided supportive evidence to our ...
Business Insider
3/11/2021 Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
... this year, our presentations will focus on results from the translational research of multiple drug candidates that have already entered into clinical development," said Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma. "These studies deepened our understanding of our drug candidate's mechanism of actions, provided supportive evidence to our ...
Business Insider
5/15/2020 Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting
... combination therapies in different mechanisms of action with drug candidates in our apoptosis-targeting pipeline, including APG-2575, APG-115 and APG-1252," said Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma. "Combination therapy is playing an increasingly important role in cancer treatment. We hope to make more research ...
PR Newswire
5/15/2020 Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting | Business & Finance | heraldchronicle.com
... combination therapies in different mechanisms of action with drug candidates in our apoptosis-targeting pipeline, including APG-2575, APG-115 and APG-1252," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Combination therapy is playing an increasingly important role in cancer treatment. We hope to make more research ...
PR Newswire
5/11/2020 Ascentage Pharma to Release Clinical Advances at 2020 ASCO Annual Meeting
... cutting-edge treatment approaches in oncology to the world. "We are excited to present the clinical advances of three of our drug candidates," said Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma. "Through these results, Ascentage Pharma is demonstrating its capabilities of global clinical development in apoptosis. We are ...
PR Newswire
5/10/2020 Ascentage Pharma to Release Clinical Advances at 2020 ASCO Annual Meeting | Business & Finance | manchestertimes.com
... cutting-edge treatment approaches in oncology to the world. "We are excited to present the clinical advances of three of our drug candidates," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Through these results, Ascentage Pharma is demonstrating its capabilities of global clinical development in apoptosis. We are ...
PR Newswire
3/23/2020 Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States
... development pipeline targeting apoptosis. Upon receiving clearance from the US FDA, we promptly initiated the trial and achieved dosing of its first patient," said Dr. Yifan Zhai , Chief Medical Officer of Ascentage Pharma. "We look forward to effectively advancing this critical clinical development program, which hopefully will soon benefit patients ...
PR Newswire
5/22/2019 Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers | Business & Finance | heraldchronicle.com
... Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4. "We are excited to present the progress of our three clinical studies," said Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, "These presentations demonstrate Ascentage's capabilities of moving multiple new drug candidates into clinical development across ...
PR Newswire
5/22/2019 Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers
... Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4 . "We are excited to present the progress of our three clinical studies," said Yifan Zhai , M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, "These presentations demonstrate Ascentage's capabilities of moving multiple new drug candidates into clinical development across ...
PR Newswire